CereVasc, Inc., a Boston, MA-based company focused on improving the treatment of patients with hydrocephalus, closed an expanded Series A financing that raised a total of $43.9m.
The round was led by the Perceptive Xontogeny Venture (PXV) Fund and ATON Partners, LLC.
Led by Dan Levangie, Chairman & CEO, and Carl B. Heilman, M.D., cofounder, Adel Malek, M.D., Ph.D. cofounder, CereVasc is a medical device company focused on the development of novel, minimally invasive treatments for patients with neurological diseases. The company’s first product, the eShunt System, is a minimally invasive cerebrospinal fluid shunt designed to avoid the need for invasive surgery and extended hospitalization associated with the current surgical treatment of hydrocephalus using ventriculo-peritoneal shunts.
The capital will be used to support the first-in-human clinical trial of the eShunt System as well as follow on clinical studies to support regulatory approvals. The first study is expected to begin enrollment during the second half of 2020.
FinSMEs
10/06/2020